Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

Genkyotex (Euronext Paris & Brussels: FR0013399474 –GKTX), abiopharmaceutical company andleader inNOXtherapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA)for the treatment of primary biliary cholangitis (PBC).

For more information, https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2020/2020.10.20_PR_GKTX_ODD_US_ff2e4.pdf